Download PDF
Thromb Haemost 2014; 112(01): 12-14
DOI: 10.1160/TH14-04-0328
Current Controversies
Schattauer GmbH

Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients’ value

Lars Wallentin
1   Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
2   Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
,
Anders Himmelmann
3   AstraZeneca Research and Development, Mölndal, Sweden
,
Robert F. Storey
4   Department of Cardiovascular Science, University of Sheffield, Sheffield, UK
,
Philippe Gabriel Steg
5   INSERM-Unité 1148, Paris, France
6   Assistance Publique-Hôpitaux de Paris; Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Paris, France
7   Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France
8   NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK
,
Robert A. Harrington
9   Department of Medicine, Stanford University, Stanford, California, USA
,
for the PLATO Publications Committee › Author Affiliations
Further Information

Publication History

Received: 09 April 2014

Accepted: 09 April 2014

Publication Date:
01 December 2017 (online)

Also available at
    Permissions and Reprints

 

Invited Editorial Focus on Viewpoint Article by Serebruany and Fortmann. Thromb Haemost 2014; 112: 4-9.

 

  • References

  • 1 Serebruany V, Fortmann SD. Underutilization of novel antiplatelet agents: myths, generics, and challenged shareholder’s value. Thromb Haemost 2014; 112: 4-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK. et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 33. 2569-2619.
    PubMedGoogle Scholar
  • 3 Hamm CW, Bassand JP, Agewall S. et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
    CrossrefPubMedGoogle Scholar
  • 4 O’Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.
    CrossrefPubMedGoogle Scholar
  • 5 Anderson JL, Adams CD, Antman EM. et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e179-347.
    CrossrefPubMedGoogle Scholar
  • 6 Storey RF, James SK, Siegbahn A. et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the plato study. Platelets. 2013 Epub ahead of print.
    PubMedGoogle Scholar
  • 7 Varenhorst C, Alstrom U, Scirica BM. et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012; 60: 1623-1630.
    CrossrefPubMedGoogle Scholar
  • 8 Mahaffey KW, Held C, Wojdyla DM. et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2014; 63: 1493-1499.
    CrossrefPubMedGoogle Scholar
  • 9 Held C, Asenblad N, Bassand JP. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Patelet In-hibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57: 672-684.
    CrossrefPubMedGoogle Scholar
  • 10 Nikolic E, Janzon M, Hauch O. et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: Results from the PLATO study. Eur Heart J 2013; 34: 220-228.
    CrossrefPubMedGoogle Scholar
  • 11 Ticagrelor for acute coronary syndrome?. Drug Ther Bull. 2011 49. 66-68.
    PubMedGoogle Scholar
  • 12 Gandjour A, Gafni A, Schlander M. Determining the price for pharmaceuticals in Germany: Comparing a shortcut for IQWiG’s efficiency frontier method with the price set by the manufacturer for ticagrelor. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 123-129.
    CrossrefPubMedGoogle Scholar